Hua Zhang1, Honggang Xia2, Lianmin Zhang1, Bin Zhang1, Dongsheng Yue1, Changli Wang3. 1. Department of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Lung Cancer Center, Huanhuxi Road, Hexi District, Tianjin, China. 2. Department of Thoracic Surgery, Tianjin Haibin people's Hospital, Tianjin, China. 3. Department of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Lung Cancer Center, Huanhuxi Road, Hexi District, Tianjin, China. Electronic address: only_zh@yeah.net.
Abstract
BACKGROUND: Our aim was to determinate the prognostic value of neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) in primary operable patients with non-small cell lung cancer (NSCLC). METHODS: Six hundred seventy-eight NSCLC patients were enrolled in this study. The prognostic significance of both markers was determined by both univariate and multivariate Cox survival analysis. The cut-off value for NLR and PLR was selected by using receiver operating characteristic curve analysis. RESULTS: Multivariate analysis showed that NLR was an independent prognostic factor for disease-free survival (hazard ratio = 1.593, 95% confidence interval [CI] 1.277 to 1.988, P < .001) and overall survival (hazard ratio = 1.624, 95% CI 1.304 to 2.022, P < .001). The area under the curve was .640 (95% CI .599 to .682, P < .001) for NLR and .547 (95% CI .503 to .590, P = .036) for PLR, indicating that NLR was superior to PLR as a predictive factor in primary operable NSCLC patients. CONCLUSIONS: Preoperative NLR represents a significant independent prognostic indicator in primary operable NSCLC patients. Our results also demonstrate that high-risk patients based on the NLR do not benefit from adjuvant chemotherapy.
BACKGROUND: Our aim was to determinate the prognostic value of neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) in primary operable patients with non-small cell lung cancer (NSCLC). METHODS: Six hundred seventy-eight NSCLCpatients were enrolled in this study. The prognostic significance of both markers was determined by both univariate and multivariate Cox survival analysis. The cut-off value for NLR and PLR was selected by using receiver operating characteristic curve analysis. RESULTS: Multivariate analysis showed that NLR was an independent prognostic factor for disease-free survival (hazard ratio = 1.593, 95% confidence interval [CI] 1.277 to 1.988, P < .001) and overall survival (hazard ratio = 1.624, 95% CI 1.304 to 2.022, P < .001). The area under the curve was .640 (95% CI .599 to .682, P < .001) for NLR and .547 (95% CI .503 to .590, P = .036) for PLR, indicating that NLR was superior to PLR as a predictive factor in primary operable NSCLCpatients. CONCLUSIONS: Preoperative NLR represents a significant independent prognostic indicator in primary operable NSCLCpatients. Our results also demonstrate that high-risk patients based on the NLR do not benefit from adjuvant chemotherapy.
Authors: Katherine A Scilla; Søren M Bentzen; Vincent K Lam; Pranshu Mohindra; Elizabeth M Nichols; Melissa A Vyfhuis; Neha Bhooshan; Steven J Feigenberg; Martin J Edelman; Josephine L Feliciano Journal: Oncologist Date: 2017-05-22